Both the companies have not disclosed the financial details of the agreement, which is for an initial term of three years.
Cardiome chief commercial officer Karim Lalji said the company is happy to have entered into this agreement with UDG Healthcare that will maintain BRINAVESS availability to our customers in Ireland.
"This agreement continues the previously established BRINAVESS distribution partnership, thereby minimizing distribution interruptions to our customers," Lalji said.
UDG Healthcare director of the Distribution and Hospitals division David Keyes said the company is happy to continue the fulfillment of orders of BRINAVESS on behalf of Cardiome for the Irish market.
"BRINAVESS is an important therapeutic option for the management of atrial fibrillation and we are excited to continue making it available to our customers," Keyes said.
Cardiome is mainly dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
It has two marketed, in-hospital, cardiology products, BRINAVESS (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary Syndrome patients.